ESMO 2023: PFS Improved With Combo of Sotorasib + Panitumumab in Patients With Metastatic CRC With KRAS G12C Mutation
960 mg sotorasib plus panitumumab had 26.4 percent overall response rate
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.